RxDoctor Payments DataLook up a doctor →

Sudhir Gokhale, MD

Psychiatry · Oak Lawn, ILNPI 1639182678

Payments from drug & device makers

$128,458in general payments, 2019–2025

Across 872 payments — averaging $147.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$43K
  • Teva Pharmaceuticals USA, Inc.$32K
  • Axsome Therapeutics, Inc.$29K
  • Johnson & Johnson$7K
  • Sunovion Pharmaceuticals Inc.$6K
  • Idorsia Pharmaceuticals US Inc$3K
  • plus $9K from 34 others

What the payments were for

  • Consulting fees$16,40013%
  • Speaking & faculty fees$87,67968%
  • Travel & lodging$6,2735%
  • Food & beverage$17,66914%
  • Education$4370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,458 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$125,948
Medicare patients
349
Services billed
1,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$150,784
Invega SustennaPaliperidone Palmitate18$70,939
RexultiBrexpiprazole28$51,935
Lurasidone Hcl85$22,259
Clozapine337$20,279
CaplytaLumateperone Tosylate11$20,263
Ziprasidone Hcl92$14,527
TrintellixVortioxetine Hydrobromide16$11,994
Quetiapine Fumarate400$7,517
Aripiprazole109$5,869
Chlorpromazine Hcl43$5,686
Olanzapine261$5,197
Divalproex Sodium ErDivalproex Sodium48$4,506
Alprazolam451$4,195
Divalproex Sodium97$3,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$897$150,78418 claims
Johnson & JohnsonInvega Sustenna$6,798$70,93918 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,285$51,93528 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$719$20,26311 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$216$11,99416 claims
Lilly USA, LLCOlanzapine$17$5,197261 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →